If that's the case, then it bodes well for ALK inhibitors. But I'm always weary of "a sure thing" as far as cancer cells are concerned. Even if EML4-ALK is an oncogenic driver, it doesn't preclude other pathways from being upregulated/downregulated in these cells.
Market Data 
Markets 
AI
